Pegfilgrastim is a protein that stimulates the production of neutrophils. The "peg" in pegfilgrastim refers to a polyethylene glycol, which is added to enlarge the Filgrastim protein. This enlargement prolongs the length of time it stays in the body, and this allows for administration in a single dose per chemotherapy cycle.

Dose is a single 6 mg subcutaneous injection once per chemotherapy cycle. Should not be given between 14 days before and 24 hours after administration of cytotoxic chemotherapy.

Decreases the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid cancers who are receiving myelosuppressive chemotherapy that is associated with an incidence of febrile neutropenia.

Bone pain, muscle ache, and injection site reaction.

Should not be used with infants, children, and adolescents weighing less than 45 kg.

Supplied in pre-filled syringes.

Refrigerate. Do not freeze. Do not shake product. Protect from light.